Fiche publication
Date publication
septembre 2007
Auteurs
Membres identifiés du Cancéropôle Est :
Pr NGUYEN Philippe
Tous les auteurs :
Szymezak J, Houdant N, Toupance O, Brandt B, Nguyen P
Résumé
Renal allograft vein thrombosis can lead to graft loss. However, it is not established whether current management for the prevention of venous thromboembolism disease can be efficiently applied for this purpose. Indeed, many parameters such as the causal nephropathy, the modalities for dialysis, the type of immunosuppression have to be taken into account. This review analyses these parameters and reports the main clinical studies which have been published to date. In the absence of definitive clinical trial allowing firm recommendations, a multidisciplinary management aimed at evaluating individual risk and benefit of antithrombotic regimen is mandatory.
Référence
Sang Thromb Vaiss. 2007 Sep;19(7):359-65
